#BEGIN_DRUGCARD DB08879

# AHFS_Codes:
92:44

# ATC_Codes:
L04AA26

# Absorption:
Cmax, 10 mg/kg, SLE patients = 313 µg/mL; AUC (0-∞), 10 mg/kg, SLE patients = 3083

# Biotransformation:
Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.

# Brand_Mixtures:
Not Available

# Brand_Names:
Benlysta

# CAS_Registry_Number:
356547-88-1

# ChEBI_ID:
Not Available

# Chemical_Formula:
C 6358 H 9904 N 1728 O 2010 S 44

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2013-05-17 18:41:17 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant monoclonal IgG antibody and is the first biological treatment approved for this indication (SLE). Avoid concomitant use with live or inactivated vaccines. FDA approved on March 9, 2011.

# Dosage_Forms:
Injection, powder, lyophilized, for solution	Intravenous

# Drug_Category:
Immunosuppressive Agents
Monoclonal Antibody

# Drug_Interactions:
Belatacept	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
Denosumab	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
Fingolimod	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.
Hydroxyurea	Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Biotech

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Belimumab

# HET_ID:
Not Available

# Half_Life:
Terminal elimination half-life, 10 mg/kg, SLE patients= 19.4 days; Distribution half-life, 10 mg/kg, SLE patients = 1.75 days

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Adjunct treatment of autoantibody-positive active systemic lupus erythematosus

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D03068

# LIMS_Drug_ID:
8892

# Mechanism_Of_Action:
Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
147 kDa

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB08879

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/benlysta-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
The most commonly-reported adverse reactions, occurring in ≥5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.

# Update_Date:
2013-05-17 19:32:58 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Belimumab

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane
single-pass type II membrane protein. Processed form:Secreted protein. Note=Also exis

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
TNFSF13B

# Drug_Target_1_GenBank_ID_Gene:
AF136293

# Drug_Target_1_GenBank_ID_Protein:
4761612

# Drug_Target_1_GeneCard_ID:
TNFSF13B

# Drug_Target_1_Gene_Name:
TNFSF13B

# Drug_Target_1_Gene_Sequence:
>858 bp
ATGGATGACTCCACAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAA
GAAATGAAACTGAAGGAGTGTGTTTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGA
TCCTCCAAAGACGGAAAGCTGCTGGCTGCAACCTTGCTGCTGGCACTGCTGTCTTGCTGC
CTCACGGTGGTGTCTTTCTACCAGGTGGCCGCCCTGCAAGGGGACCTGGCCAGCCTCCGG
GCAGAGCTGCAGGGCCACCACGCGGAGAAGCTGCCAGCAGGAGCAGGAGCCCCCAAGGCC
GGCTTGGAGGAAGCTCCAGCTGTCACCGCGGGACTGAAAATCTTTGAACCACCAGCTCCA
GGAGAAGGCAACTCCAGTCAGAACAGCAGAAATAAGCGTGCCGTTCAGGGTCCAGAAGAA
ACAGTCACTCAAGACTGCTTGCAACTGATTGCAGACAGTGAAACACCAACTATACAAAAA
GGATCTTACACATTTGTTCCATGGCTTCTCAGCTTTAAAAGGGGAAGTGCCCTAGAAGAA
AAAGAGAATAAAATATTGGTCAAAGAAACTGGTTACTTTTTTATATATGGTCAGGTTTTA
TATACTGATAAGACCTACGCCATGGGACATCTAATTCAGAGGAAGAAGGTCCATGTCTTT
GGGGATGAATTGAGTCTGGTGACTTTGTTTCGATGTATTCAAAATATGCCTGAAACACTA
CCCAATAATTCCTGCTATTCAGCTGGCATTGCAAAACTGGAAGAAGGAGATGAACTCCAA
CTTGCAATACCAAGAGAAAATGCACAAATATCACTGGATGGAGATGTCACATTTTTTGGT
GCATTGAAACTGCTGTGA

# Drug_Target_1_General_Function:
Involved in tumor necrosis factor receptor binding

# Drug_Target_1_General_References:
10331498	Shu HB, Hu WH, Johnson H: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol. 1999 May;65(5):680-3.
10359578	Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999 Jun 7;189(11):1747-56.
10398604	Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999 Jul 9;285(5425):260-3.
10973284	Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, McCabe S, Qiu WR, Kornuc M, Xia XZ, Guo J, Stolina M, Boyle WJ, Sarosi I, Hsu H, Senaldi G, Theill LE: APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000 Sep;1(3):252-6.
11827482	Karpusas M, Cachero TG, Qian F, Boriack-Sjodin A, Mullen C, Strauch K, Hsu YM, Kalled SL: Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol. 2002 Feb 1;315(5):1145-54.
11853672	Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G: Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell. 2002 Feb 8;108(3):383-94.
11862220	Oren DA, Li Y, Volovik Y, Morris TS, Dharia C, Das K, Galperina O, Gentz R, Arnold E: Structural basis of BLyS receptor recognition. Nat Struct Biol. 2002 Apr;9(4):288-92.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_1_HGNC_ID:
HGNC:11929

# Drug_Target_1_HPRD_ID:
04914

# Drug_Target_1_ID:
1467

# Drug_Target_1_Locus:
13q32-34

# Drug_Target_1_Molecular_Weight:
31223

# Drug_Target_1_Name:
Tumor necrosis factor ligand superfamily member 13B

# Drug_Target_1_Number_of_Residues:
285

# Drug_Target_1_PDB_ID:
1OSG

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00229	TNF

# Drug_Target_1_Protein_Sequence:
>Tumor necrosis factor ligand superfamily member 13B
MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCC
LTVVSFYQVAALQGDLASLRAELQGHHAEKLPAGAGAPKAGLEEAPAVTAGLKIFEPPAP
GEGNSSQNSRNKRAVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEE
KENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETL
PNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the B-cell response

# Drug_Target_1_SwissProt_ID:
Q9Y275

# Drug_Target_1_SwissProt_Name:
TN13B_HUMAN

# Drug_Target_1_Synonyms:
B cell-activating factor
B lymphocyte stimulator
BAFF
BLyS
CD257 antigen
Dendritic cell- derived TNF-like molecule
TALL-1
TNF- and APOL- related leukocyte expressed ligand 1

# Drug_Target_1_Theoretical_pI:
6.15

# Drug_Target_1_Transmembrane_Regions:
47-67

#END_DRUGCARD DB08879
